FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Philip Mack

Research Profile

Disorders

Procedures

Chemicals & Drugs

Anatomy

Tumor Cell Line

Concepts & Ideas

Physiology

Co-author Network

Publications

TOP 3
Tianhong Li; Philip C Mack; Hsing-Jien Kung; David R Gandara
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
Philip C Mack; David R Gandara; Primo Lara
Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach.
David R Gandara; Neal Goodwin; Karen Kelly; Primo Lara; Tianhong Li; Philip C Mack; Suzanne Miyamoto; Laurel Beckett; Mary W Redman
Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Philip Mack (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Tianhong Li; Philip C Mack; Hsing-Jien Kung; David R Gandara
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(8):1039-49.
2012: Philip C Mack; David R Gandara; Primo Lara
Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach.
Expert review of anticancer therapy 2012;12(12):1591-6.
2012: David R Gandara; Neal Goodwin; Karen Kelly; Primo Lara; Tianhong Li; Philip C Mack; Suzanne Miyamoto; Laurel Beckett; Mary W Redman
Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.
Clinical lung cancer 2012;13(5):321-5.
2012: Danielle C Chinn; William S Holland; Janet Yoon; Ted Zwerdling; Philip C Mack
Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines.
Pediatric blood & cancer 2012;58(6):885-90.
2012: Lanfang Bai; Hsing-Jien Kung; Philip C Mack; Joon-ha Ok; Joy C Yang; Christopher P Evans
Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
International journal of cancer. Journal international du cancer 2012;130(11):2693-702.
2012: Helen K Chew; S Christensen; Regina Gandour-Edwards; B Gitlitz; H Linden; Philip C Mack; L J Solis; G Somlo; Xiaowei Yang; A M Davies
Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(4):1023-9.
2012: Tianhong Li; Thehang Luu; Philip C Mack; Kim A Margolin; Sanjiv S Agarwala; Scott D Christensen; Paul H Frankel; Primo Lara; David R Gandara
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
Investigational new drugs 2012;30(2):741-8.
2012: Peter M Wilson; Melissa J LaBonte; Heinz-Josef Lenz; Philip C Mack; Robert D Ladner
Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer.
Molecular cancer therapeutics 2012;11(3):616-28.
2012: Thomas J Semrad; Philip C Mack
Fibroblast growth factor signaling in non-small-cell lung cancer.
Clinical lung cancer 2012;13(2):90-5.
2012: Christopher M Mahaffey; Hongqiao Zhang; Philip C Mack; William Holland; Nichole C Mahaffey; David R Gandara; Henry Jay Forman
Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(1):34-9.
2012: William S Holland; Danielle C Chinn; Jose E Pietri; Philip C Mack; Clifford G Tepper; David R Gandara; Primo Lara
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
Cancer chemotherapy and pharmacology 2012;69(1):185-94.
2011: Randeep Sangha; Laurel Beckett; Angela M Davies; Paul J Hesketh; Primo Lara; Derick H Lau; Tianhong Li; Philip C Mack; Natasha Perkins; David R Gandara
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(12):2112-9.
2011: Cheryl Ho; Randeep Sangha; Laurel Beckett; Michael Tanaka; Derick H Lau; Daniel Eisen; Rachel A Burich; Paul A Luciw; Imran Khan; Philip C Mack; David R Gandara; Angela M Davies
Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study.
Investigational new drugs 2011;29(4):680-7.
2011: Sacha I Rothschild; Oliver Gautschi; Primo Lara; Philip C Mack; David R Gandara
Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
Current opinion in oncology 2011;23(2):150-7.
2011: Primo Lara; Jeff Longmate; Karen Reckamp; Barbara Gitlitz; Athanassios Argiris; Suresh Ramalingam; Chandra P Belani; Philip C Mack; Derick H Lau; Mariana Koczywas; John J Wright; Frances A Shepherd; Natasha B Leighl; David R Gandara
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Clinical lung cancer 2011;12(1):33-7.
2010: David R Gandara; Peter Grimminger; Philip C Mack; Primo Lara; Tianhong Li; Peter V Danenberg; Kathleen D Danenberg
Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(12):1933-8.
2010: Roy S Herbst; Karen Kelly; Kari Chansky; Philip C Mack; Wilbur A Franklin; Fred R Hirsch; James N Atkins; Shaker R Dakhil; Kathy S Albain; Edward S Kim; Mary Redman; John J Crowley; David R Gandara
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(31):4747-54.
2010: Suresh S Ramalingam; Chandra P Belani; Philip C Mack; Everett E Vokes; Jeffrey Longmate; Ramaswamy Govindan; Marianna Koczywas; S Percy Ivy; David R Gandara
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(8):1279-84.
2010: Tanya B Dorff; Bryan Goldman; Jacek Pinski; Philip C Mack; Primo Lara; Peter J Van Veldhuizen; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha Hussain
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(11):3028-34.
2010: David R Gandara; Philip C Mack; Tianhong Li; Primo Lara; Roy S Herbst
[Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012].
Zhongguo fei ai za zhi = Chinese journal of lung cancer 2010;13(3):238-41.
2010: Tianhong Li; Primo Lara; Philip C Mack; Roman Perez-Soler; David R Gandara
Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.
Current drug targets 2010;11(1):85-94.
2010: Jamie L McCall; Rebekah A Burich; Philip C Mack
GCP, a genistein-rich compound, inhibits proliferation and induces apoptosis in lymphoma cell lines.
Leukemia research 2010;34(1):69-76.
2009: Philip C Mack; William S Holland; Rebekah A Burich; Randeep Sangha; Leslie J Solis; Yueju Li; Laurel Beckett; Primo Lara; Angela M Davies; David R Gandara
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(12):1466-72.
2009: Michael S Gordon; Michael Hussey; Raymond B Nagle; Primo Lara; Philip C Mack; Janice Dutcher; Wolfram Samlowski; Joseph I Clark; David I Quinn; Chong-Xian Pan; David Crawford
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5788-93.
2009: David R Gandara; Philip C Mack; Tianhong Li; Primo Lara; Roy S Herbst
Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012.
Clinical lung cancer 2009;10(6):392-4.
2009: Peter J Van Veldhuizen; Joseph I Clark; Regina Gandour-Edwards; Michael Hussey; Marianne K Lange; Primo Lara; Philip C Mack; David E Crawford
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
American journal of clinical oncology 2009;32(5):453-9.
2009: Shun-Ichi Isa; Tomoya Kawaguchi; Satoshi Teramukai; Koichi Minato; Yoshinobu Ohsaki; Kazuhiko Shibata; Toshirou Yonei; Kenji Hayashibara; Masanori Fukushima; Masaaki Kawahara; Kiyoyuki Furuse; Philip C Mack
Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(9):1104-10.
2009: Ramesh K Ramanathan; Chandra P Belani; Deepti A Singh; Michael Tanaka; Heinz-Josef Lenz; Yun Yen; Hedy L Kindler; Syma Iqbal; Jeff Longmate; Philip C Mack; Georg Lurje; Regina Gandour-Edwards; Janet Dancey; David R Gandara
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Cancer chemotherapy and pharmacology 2009;64(4):777-83.
2009: David R Gandara; Tomoya Kawaguchi; John Crowley; James Moon; Kiyoyuki Furuse; Masaaki Kawahara; Satoshi Teramukai; Yuichiro Ohe; Kaoru Kubota; Stephen K Williamson; Oliver Gautschi; Heinz-Josef Lenz; howard mcleod; Primo Lara; Charles Arthur Coltman; Masahiro Fukuoka; Nagahiro Saijo; Masanori Fukushima; Philip C Mack
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3540-6.
2009: Christopher M Mahaffey; Hongqiao Zhang; Alessandra Rinna; William Holland; Philip C Mack; Henry Jay Forman
Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma.
Free radical biology & medicine 2009;46(12):1650-7.
2009: David R Gandara; Primo Lara; Philip C Mack; Giorgio Scagliotti
Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
Clinical lung cancer 2009;10(3):148-50.
2009: CC Olsen; Tracey E Schefter; Honglin Chen; Madeleine Kane; Stephen Leong; Martin D McCarter; Yang Chen; Philip C Mack; S Gail Eckhardt; Gregory V Stiegmann; David Raben
Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy.
American journal of clinical oncology 2009;32(2):115-21.
2009: Phillip R Purnell; Philip C Mack; Clifford G Tepper; Christopher P Evans; Tim P Green; Paul H Gumerlock; Primo Lara; David R Gandara; Hsing-Jien Kung; Oliver Gautschi
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(4):448-54.
2009: Randeep Sangha; Primo Lara; Philip C Mack; David R Gandara
Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
Current opinion in oncology 2009;21(2):116-23.
2008: Rebekah A Burich; William S Holland; Ruth L Vinall; Clifford G Tepper; Ralph W deVere White; Philip C Mack
Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
BJU international 2008;102(10):1458-66.
2008: Philip C Mack; Mary W Redman; Kari Chansky; Stephen K Williamson; Nichole C Farneth; Primo Lara; Wilbur A Franklin; Quynh-Thu Le; John J Crowley; David R Gandara
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4771-6.
2008: Paul J Hesketh; Kari Chansky; Antoinette J Wozniak; Fred R Hirsch; Anna Spreafico; James Moon; Philip C Mack; Benjamin T Marchello; Wilbur A Franklin; John J Crowley; David R Gandara
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(9):1026-31.
2008: Hong-Lin Devlin; Philip C Mack; Rebekah A Burich; Paul H Gumerlock; Hsing-Jien Kung; maria mudryj; Ralph W deVere White
Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells.
Molecular cancer research : MCR 2008;6(5):808-18.
2008: Oliver Gautschi; Clifford G Tepper; Phillip R Purnell; Yoshihiro Izumiya; Christopher P Evans; Tim P Green; Pierre Y Desprez; Primo Lara; David R Gandara; Philip C Mack; Hsing-Jien Kung
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer.
Cancer research 2008;68(7):2250-8.
2008: Oliver Gautschi; Jim Heighway; Philip C Mack; Phillip R Purnell; Primo Lara; David R Gandara
Aurora kinases as anticancer drug targets.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(6):1639-48.
2008: Randeep Sangha; Primo Lara; Philip C Mack; David R Gandara
Targeted therapies in non-small-cell lung cancer: a paradigm in evolution.
Clinical lung cancer 2008;9 Suppl 3():S90-1.
2008: Oliver Gautschi; Philip C Mack; Angela M Davies; David M Jablons; Rafael Rosell; David R Gandara
Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.
Clinical lung cancer 2008;9 Suppl 3():S129-38.
2007: Christopher M Mahaffey; Angela M Davies; Primo Lara; Brandi Pryde; William Holland; Philip C Mack; Paul H Gumerlock; David R Gandara
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Clinical lung cancer 2007;8(9):548-53.
2007: Oliver Gautschi; B Huegli; A Ziegler; Mathias Gugger; Jim Heighway; Daniel Ratschiller; Philip C Mack; Paul H Gumerlock; Hsing-Jien Kung; R A Stahel; David R Gandara; Daniel C Betticher
Origin and prognostic value of circulating KRAS mutations in lung cancer patients.
Cancer letters 2007;254(2):265-73.
2007: Angela M Davies; Primo Lara; Philip C Mack; David R Gandara
Incorporating bortezomib into the treatment of lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4647-51.
2007: Christopher W Ryan; Bryan H Goldman; Primo Lara; Philip C Mack; Tomasz M Beer; Catherine M Tangen; Dianne Lemmon; Chong-Xian Pan; Harry A Drabkin; E David Crawford
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3296-301.
2007: Cheryl Ho; Angela Davies; Philip C Mack; David R Gandara
Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.
Clinical lung cancer 2007;8(7):420-4.
2007: Clifford G Tepper; Ruth L Vinall; Christopher B Wee; Lingru Xue; Xu-Bao Shi; Rebekah Burich; Philip C Mack; Ralph W deVere White
GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
The Prostate 2007;67(5):521-35.
2007: David R Gandara; Angela M Davies; Oliver Gautschi; Philip C Mack; Derick H Lau; Primo Lara; Fred R Hirsch
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.
Clinical lung cancer 2007;8 Suppl 2():S61-7.
2007: E C Nelson; Christopher P Evans; Philip C Mack; Ralph W deVere White; Primo Lara
Inhibition of Akt pathways in the treatment of prostate cancer.
Prostate cancer and prostatic diseases 2007;10(4):331-9.
2006: Primo Lara; Kari Chansky; Angela M Davies; Wilbur A Franklin; Paul H Gumerlock; Perry P Guaglianone; James N Atkins; Nichole Farneth; Philip C Mack; John J Crowley; David R Gandara
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(9):996-1001.
2006: Oliver Gautschi; Philip C Mack; Angela M Davies; Primo Lara; David R Gandara
Aurora kinase inhibitors: a new class of targeted drugs in cancer.
Clinical lung cancer 2006;8(2):93-8.
2006: Angela M Davies; Cheryl Ho; Primo Lara; Philip C Mack; Paul H Gumerlock; David R Gandara
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Clinical lung cancer 2006;7(6):385-8.
2005: David R Gandara; Eric Vallières; Laurie E Gaspar; Karen Kelly; Kathy S Albain; Roy S Herbst; Primo Lara; Philip C Mack; Paul H Gumerlock; John J Crowley
Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy.
Clinical lung cancer 2005;7 Suppl 3():S93-7.
2005: Primo Lara; Richard J Bold; Philip C Mack; Angela M Davies; Paul H Gumerlock; David R Gandara
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
Clinical lung cancer 2005;7 Suppl 2():S67-71.
2005: Angela M Davies; Primo Lara; Philip C Mack; Paul H Gumerlock; Richard J Bold; David R Gandara
Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Clinical lung cancer 2005;7 Suppl 2():S59-63.
2005: David R Gandara; Samir Narayan; Primo Lara; Zelanna Goldberg; Angela Davies; Derick H Lau; Philip C Mack; Paul H Gumerlock; Srinivasan Vijayakumar
Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13 Pt 2):5057s-5062s.
2005: Primo Lara; Philip C Mack; Timothy W Synold; Paul Frankel; Jeff Longmate; Paul H Gumerlock; James Doroshow; David R Gandara
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4444-50.
2004: Philip C Mack; Angela A Jones; Matthew H Gustafsson; David R Gandara; Paul H Gumerlock; Zelanna Goldberg
Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells.
Radiation research 2004;162(6):623-34.
2004: Primo Lara; Paul H Gumerlock; Philip C Mack; Derick H Lau; Regina Gandour-Edwards; Martin J Edelman; Kathy S Albain; Lisa Y Law; Jeff Longmate; Paul Frankel; Gayatri P Reddy; Valerie Israel; James Doroshow; David R Gandara
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
Clinical lung cancer 2004;6(2):102-7.
2004: Xu-Bao Shi; Ai-Hong Ma; Clifford G Tepper; Liang Xia; Jeffrey P Gregg; Regina Gandour-Edwards; Philip C Mack; Hsing-Jien Kung; Ralph W deVere White
Molecular alterations associated with LNCaP cell progression to androgen independence.
The Prostate 2004;60(3):257-71.
2004: Angela M Davies; Philip C Mack; Primo Lara; Derick H Lau; Kathleen Danenberg; Paul H Gumerlock; David R Gandara
Predictive molecular markers: has the time come for routine use in lung cancer?
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2(2):125-31.
2004: Primo Lara; Angela M Davies; Philip C Mack; Melinda M Mortenson; Richard J Bold; Paul H Gumerlock; David R Gandara
Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
Seminars in oncology 2004;31(1 Suppl 1):40-6.
2004: Regina Gandour-Edwards; Philip C Mack; Ralph W deVere White; Paul H Gumerlock
Abnormalities of apoptotic and cell cycle regulatory proteins in distinct histopathologic components of benign prostatic hyperplasia.
Prostate cancer and prostatic diseases 2004;7(4):321-6.
2003: Primo Lara; David I Quinn; Kim Margolin; Frederick J Meyers; Jeff Longmate; Paul Frankel; Philip C Mack; Corinne Turrell; Peter Valk; Jyotsna Rao; Penelope Buckley; Ted Wun; Robert C Gosselin; Irina Galvin; Paul H Gumerlock; Heinz-Josef Lenz; James Doroshow; David R Gandara
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4772-81.
2003: Primo Lara; Paul Frankel; Philip C Mack; Paul H Gumerlock; Irina Galvin; Cynthia L Martel; Jeff Longmate; James Doroshow; Heinz-Josef Lenz; Derick H Lau; David R Gandara
Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4356-62.
2003: Philip C Mack; Angela M Davies; Primo Lara; Paul H Gumerlock; David R Gandara
Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;41 Suppl 1():S89-96.
2003: Philip C Mack; David R Gandara; Alvin H Lau; Primo Lara; Martin J Edelman; Paul H Gumerlock
Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
Cancer chemotherapy and pharmacology 2003;51(4):337-48.
2003: Angela M Davies; Primo Lara; Philip C Mack; David R Gandara
Docetaxel in non-small cell lung cancer: a review.
Expert opinion on pharmacotherapy 2003;4(4):553-65.
2003: Angela M Davies; David R Gandara; Primo Lara; Philip C Mack; Derick H Lau; Paul H Gumerlock
Antisense oligonucleotides in the treatment of non-small-cell lung cancer.
Clinical lung cancer 2003;4 Suppl 2():S68-73.
2002: David R Gandara; Primo Lara; Zelanna Goldberg; Quynh T Le; Philip C Mack; Derick H Lau; Paul H Gumerlock
Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.
Seminars in oncology 2002;29(1 Suppl 4):102-9.
2001: David R Gandara; Primo Lara; Derick H Lau; Philip C Mack; Paul H Gumerlock
Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 3():S75-80.
2001: Primo Lara; David R Gandara; Jeff Longmate; Paul H Gumerlock; Derick H Lau; Martin J Edelman; Regina Gandour-Edwards; Philip C Mack; Valerie Israel; James Raschko; Paul Frankel; E A Perez; Heinz-Josef Lenz; James Doroshow
Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial.
Cancer chemotherapy and pharmacology 2001;48(1):22-8.
2001: Linda A Kroger; Gerald L DeNardo; Paul H Gumerlock; Cheng-Yi Xiong; Michelle D Winthrop; Xu-Bao Shi; Philip C Mack; T Leshchinsky; Sally J DeNardo
Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 2001;16(3):213-25.
1999: Philip C Mack; David R Gandara; C Bowen; Martin J Edelman; T Paglieroni; Joachim B Schnier; Edward P Gelmann; Paul H Gumerlock
RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2596-604.
1999: L M Gumbiner; Paul H Gumerlock; Philip C Mack; SG Chi; Ralph W deVere White; J L Mohler; T G Pretlow; JV Tricoli
Overexpression of cyclin D1 is rare in human prostate carcinoma.
The Prostate 1999;38(1):40-5.
1998: Philip C Mack; SG Chi; Frederick J Meyers; S L Stewart; Ralph W deVere White; Paul H Gumerlock
Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade.
The Prostate 1998;34(2):145-51.
1997: G Morris; Sally J DeNardo; Gerald L DeNardo; T Leshchinsky; B Wu; Philip C Mack; Michelle D Winthrop; Paul H Gumerlock
Decreased C-MYC and BCL2 expression correlates with methylprednisolone-mediated inhibition of Raji lymphoma growth.
Biochemical and molecular medicine 1997;60(2):108-15.
1995: Sally J DeNardo; Paul H Gumerlock; Michelle D Winthrop; Philip C Mack; S G Chi; Kathleen R Lamborn; Sui Shen; Laird A Miers; Ralph W deVere White; Gerald L DeNardo
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
Cancer research 1995;55(23 Suppl):5837s-5841s.